Last reviewed 2026-04-20 · How we verify

Micorene (CROTETAMIDE)

Phase 2 active Small molecule Quality 19/100

Micorene (generic name: CROTETAMIDE) is a crotetamide drug. It is currently in Phase 2 development.

Crotetamide works by inhibiting cellular processes, but the exact mechanism is unknown.

Crotetamide, also known as Micorene, is a small molecule drug in the crotetamide class. Its target and exact mechanism of action are unknown, but it is believed to work by inhibiting certain cellular processes. Crotetamide's commercial status and approved indications are not publicly available. As a result, its safety profile and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CROTETAMIDE
Drug class	crotetamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells are like a city with many different buildings and roads. Crotetamide is like a traffic cop that tries to stop certain processes from happening, but we don't know exactly which roads it's trying to block or why. This can help slow down the growth of certain cells, but it's a complex process that needs more research to fully understand.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Micorene CI brief — competitive landscape report
Micorene updates RSS · CI watch RSS

Frequently asked questions about Micorene

What is Micorene?

Micorene (CROTETAMIDE) is a crotetamide drug.

How does Micorene work?

Crotetamide works by inhibiting cellular processes, but the exact mechanism is unknown.

What is the generic name of Micorene?

CROTETAMIDE is the generic (nonproprietary) name of Micorene.

What drug class is Micorene in?

Micorene belongs to the crotetamide class. See all crotetamide drugs at /class/crotetamide.

What development phase is Micorene in?

Micorene is in Phase 2.

Drug class: All crotetamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing